IRAK1 and systemic lupus erythematosus: These considerations suggest that only drugs targeting a core component of the MyD88-IRAK4-IRAK1 pathway (Fig 9) will have the potential to suppress all facets of the lupus phenotype and led us to treat the ABIN1[D485N] mice with an orally active IRAK4 inhibitor.